Daily Brief Archive: July 10, 2026 — U.S. & Hong Kong Stock Analysis

Free preview

U.S. Markets

  • S&P +0.8%, Nasdaq +1.3% — chips led the tape right through the Iran escalation
  • SMH +2.5% with MU +4.5%, AMD +5.7%, SNDK +7.6%; falling crude defused the inflation alarm
  • SK Hynix's IPO was 7x oversubscribed at $149; it debuts on Nasdaq today as SKHY
  • IONS -24% on the failed AstraZeneca-partnered ATTR-CM Phase 3; BBIO +15% as the rival winner
  • COST -4.2%: June comps of +8.8% missed, and a 42x multiple has no room for 'merely in line'

Hong Kong

  • HSI +0.57% in a structural tape: property, materials and brokers strong, big tech soft
  • The memory chain surged into the SKHY debut — GigaDevice ripped 22% in a day
  • WuXi Biologics +5.6%: UBS lifted its target to HK$51.10 amid buybacks and upbeat CRO pre-announcements
  • MiniMax slid another 7.5% into oversold territory — unlock supply still hasn't cleared
  • Alibaba extended gains at the highs as the China AI re-rating entered day three

Today's Watchlist

  • SKHY's debut is the memory sector's pricing ceremony — Micron's direct comp has arrived
  • Today's action: re-opened the RIVN long (offering overhang cleared); all other 46 positions held
  • Delta reports premarket today — summer fares are the consumer thermometer
  • Earnings season nears: SYF 7/21, TSLA 7/22 — volatility ratchets up from here
  • The Iran conflict is escalating yet markets are desensitizing — falling crude is the macro signal that matters

Deep Dives (6 names)

Neutral
Score7/10Day move -23.9%Event ATTR-CM Phase 3 missed primary endpointMarket cap lost ~$3.2BRelative volume 8.3x

Technicals — Down 23.9% to $64.27 on 8.3x volume — the worst session since March 2021 — one candle slicing through every moving average (the 20-, 50- and 200-day all cluster near $76). RSI at 31.1 approaches oversold without being extreme, and the $75–78 gap won't fill anytime soon.

Fundamentals — The AstraZeneca-partnered Phase 3 CARDIO-TTRansform trial of eplontersen (Wainua) in ATTR cardiomyopathy missed its primary endpoint — no statistically significant reduction in CV death and recurrent events through week 140 versus placebo. ATTR-CM is a multi-billion-dollar market, and that growth curve just got erased; the approved polyneuropathy indication and the rest of the pipeline stand, but the valuation lost a pillar.

News — Jefferies and BofA both cut targets to $90 (from $113 and $111, Buys intact) the same day, and law firms have launched investigation notices. Yet StockTwits retail is euphoric — 'opportunity of a lifetime' trended. A day of institutions cutting targets while retail yells bottom.

Short-term · 1–3 weeks
Neutral Sidelines

Day one of a pipeline-failure crash is never the bottom: index rebalancing, risk-desk liquidations and target cuts roll on for days. 8.3x volume says the hand-off has only started.

Entry No knife-catching; reassess after volume dries up and the target-cut wave completesStop —Target —
Long-term · months+
Neutral

The antisense platform remains a scarce technology asset with an approved-product floor; but filling the ATTR-CM hole needs new pipeline data, and rebuilding trust takes time.

  • AstraZeneca dialing back commercial investment
  • Law-firm investigations and potential class actions
  • A dense readout calendar keeps volatility elevated
Community Voices
  • StockTwits · 'Opportunity of a lifetime' — the board chants it every time a pipeline blows up; the one right call gets remembered, the nine wrong ones never come upOriginal ↗
Institutional Views
  • 华尔街共识 · 26 analysts average $96.70 (+50% vs. spot) — a stale number that predates the trial miss and is being cut in batches
  • Jefferies · Target $113→$90, Buy maintained: the polyneuropathy franchise and remaining pipeline hold valueSource ↗
  • BofA · Target $111→$90, Buy maintainedSource ↗
Neutral
Score7/10Day move +15.1%RSI(14) 86.8Triple catalyst Rival's miss + infigratinib Ph3 win + $1B raisePosition All-time high

Technicals — Up 15.1% to $90.17, an all-time high ($91.67 intraday) on 3.7x volume, RSI at a scorching 86.8. Price sits 25% above the 20-day ($72) — an extension at record extremes. The momentum is real, but any retest will be fast and deep.

Fundamentals — Three catalysts resonating: the rival eplontersen ATTR-CM failure directly widens Attruby's moat; oral infigratinib hit all primary and key secondary endpoints in Phase 3 achondroplasia (NEJM-published) with NDA/MAA filings planned for 2026; and a $1B preferred raise led by Sixth Street, KKR and HealthCare Royalty. Commercial, pipeline and balance sheet all thickened at once.

News — TheStreet's headline said it plainly: 'BridgeBio jumps after rival heart drug fails.' The ATTR-CM competitive map was redrawn overnight — oral Attruby versus Pfizer's aging incumbent, with the gene-silencing camp down a major contender.

Short-term · 1–3 weeks
Neutral Sidelines

The fundamental inflection is real and durable (competitive map, pipeline, cash), but +15% in a day at RSI 86.8 offers terrible entry odds. A textbook 'core watchlist, wait for the retest' name.

Entry A low-volume retest of $78–82 (the gap's upper rim) is the entry to want; no chasing RSI 87Stop —Target —
Long-term · months+
Accumulate

Attruby's first-mover position strengthens with a rival gone, infigratinib opens the second indication curve, and the $1B raise removes dilution suspense — the rare-disease platform's compounding structure has taken shape.

  • Price competition from Pfizer and remaining ATTR rivals
  • Infigratinib approval or launch pace disappointing
  • Structural costs of the preferred financing
Community Voices
  • StockTwits · IONS's funeral became BBIO's wedding, with the same posters crying in the morning and toasting by afternoon — biotech's zero-sum game has never been subtleOriginal ↗
Institutional Views
  • 华尔街共识 · 24 analysts, average target $106.40 (+18% vs. spot), 1.17 — strong-buy territory
  • QuiverQuant · The $1B raise led by Sixth Street, HealthCare Royalty and KKR paves the commercialization runwaySource ↗
Neutral
Score6/10RSI(14) 34.8Day move -4.2%June comps +8.8% vs. 10.6% expectedForward P/E ~42x

Technicals — Down 4.2% to $912.97 on 1.5x volume, breaking the 200-day ($956.90), now at the 27th percentile of its 52-week range. RSI 34.8 is weak but not oversold, the since-May pattern of lower rebound highs remains a clean distribution structure, and next support sits near $880 (the 52-week-low shelf).

Fundamentals — June net sales +10.6%, comps +8.8% — excellent in absolute terms, but below the 10.6% expected and a clear deceleration from May's 12.5%; Canada comps of just +3.7% plus FX and gas deflation dented reported numbers. JPMorgan cut its target to $1,100 the same day. The franchise is fine; the problem is purely the multiple — 42x forward prices in 'beats forever.'

News — After a second straight month of 'in line but no upside,' profit-takers headed out. Seeking Alpha called it 'a small June swoon'; the market voted with -4.2%. Richly valued defensives are being systematically repriced.

Short-term · 2–4 weeks
Neutral Sidelines

A premium name below its 200-day needs time, not hope — grinding from 42x toward 35x doesn't finish in a week. Membership renewal rates are the hole card; let the next monthly report play it.

Entry A dry-volume hammer near $880 allows a light left-side probe; no right-side trade until the 200-day ($957) is reclaimedStop $865Target $955
Long-term · months+
Neutral

The membership model is bulletproof, but today's price still pays for perfection; odds reappear only once the multiple digests below ~35x.

  • Continued comp deceleration triggers a multiple-and-estimate double hit
  • Tariffs lifting imported-goods costs
  • International slowdown against tough comparisons
Community Voices
  • StockTwits · 'I've waited three years for sub-$900' — those about to get their wish should ask why it's finally fallingOriginal ↗
Institutional Views
  • 华尔街共识 · 39 analysts, average target $1,094 (+20% vs. spot), 1.51 rating
  • JPMorgan · Target cut to $1,100 — the deceleration pressures the valuation premiumSource ↗
Long
Score7/10Day move +8.8%Offering priced $15.50/share, $1.2B, closed 7/9Overallotment Fully exercised (11.25M shares)FY delivery guide Raised to 65–70k

Technicals — Up 8.8% to $18.12, a 17% premium to the $15.50 offer, reclaiming the converged 20/50/200-day cluster ($15.70–16.40) in one move. 1.6x volume confirms real demand and the offering-crash gap has fully filled — a V-shaped repair after the supply shock cleared.

Fundamentals — The offering priced at $15.50, raised $1.2B and closed on 7/9 with the overallotment fully exercised — institutions loaded up at that level. Add Q2 deliveries of 12,194 beating guidance, the full-year raise to 65–70k, and DoE loan matching funds in place: dilution bought certainty for the R2 ramp.

News — Benzinga flagged the moving-average reclaim; ts2 noted the climb back over deal price with focus on 42,441 YTD deliveries. Last week's panic supply became this week's institutional cost basis.

Short-term · 2–4 weeks
Long Bullish

Re-opening the long: the reason for the last exit (offering overhang) is gone — priced, closed, overallotment taken, every average reclaimed, guidance raised. Stop at $16.20 (under the MA cluster); a slide back below the $15.50 deal price would falsify the repair.

Entry $17.2~18.3Stop $16.20Target $22
Long-term · months+
Neutral

The R2 ramp and DoE-backed capacity story now has funding certainty, but profitability remains distant; treat it as a catalyst-driven trade, not a buy-and-hold conviction.

  • Losing the $15.50 deal-price floor turns it into resistance
  • Q2 margins and the R2 ramp cadence
  • EV demand and tariff-policy swings
Signal BacktestCumulative -11.49%price itself +9.88%0/1 closed trades wonprofitable since 07-07
  • 07-04Long$18.63 → closed $16.4907-08-11.49%
  • 07-10Long$18.12 → open → $18.12+0.00%
Community Voices
  • StockTwits · Last week's 'dilution vampires' posts have become 'smart to raise at highs' praise — retail memory is exactly one green candle longOriginal ↗
Institutional Views
  • 华尔街共识 · 29 analysts average $18.70 (at spot), 1.74 rating — targets get remarked as the raise digests and guidance lifts
  • StockTitan · 75M shares priced at $15.50 for ~$1.2B, overallotment fully exercisedSource ↗
Neutral
Score6/10Day move -5.7%Event Wainua ATTR-CM Phase 3 miss (with Ionis)RSI(14) 43.5Relative volume 3.0x

Technicals — Down 5.7% to $178.49 on 3x volume, breaking below the triple-average cluster near $183 — overnight, the support band became a resistance band. RSI 43.5 is soft-neutral, mid-range on the year, with no near-term structure to lean on.

Fundamentals — The Wainua ATTR-CM expansion failure removes a multi-billion-dollar growth option, but it was one option inside a sprawling oncology-respiratory-rare-disease portfolio. For Ionis it was a valuation pillar collapsing; for AstraZeneca, an option expiring worthless — the same event at two orders of magnitude.

News — The same trial data that cratered Ionis 24% sent this down 5.7% on 3x volume — among its larger single-day drops of 2026. BridgeBio's Attruby emerges as the ATTR-CM market's direct beneficiary.

Short-term · 2–4 weeks
Neutral Sidelines

A defensive mega-pharma below all its averages usually grinds sideways rather than bouncing; gap repair needs a fresh catalyst. Dividend and valuation set the floor, but there's no near-term entry signal.

Entry Reassess above the $183 triple-average band; support below sits near $172Stop —Target —
Long-term · months+
Neutral

The oncology compounding machine isn't broken — ATTR-CM was one option among many; but with the growth story downshifted, a re-rating depends on the H2 oncology data cycle.

  • A dense readout calendar — a second miss would damage the valuation frame
  • Drug-pricing policy and tariff risk
  • Impairments on Wainua commercial investment
Community Voices
  • StockTwits · 'Only down 5.7%, the market doesn't care' — what the market cares about was never this failure, but how much multiple you dare pay before the next readoutOriginal ↗
Institutional Views
  • 华尔街共识 · 31 analysts, average target $222 (+24% vs. spot), 1.27 rating
Neutral
Score6/10Day move +10.0%Catalyst 1,200-acre powered Texas site, 2GW AI campus planNew coverage Citizens Outperform, $24 targetCatch No tenant signed yet

Technicals — Up 10% to $13.22 after an 18% intraday spike — the fade shows real supply above the 20-day ($13.70). RSI 49 is neutral, the 200-day ($12.40) anchors below, and only a $14 break exits the six-month box.

Fundamentals — The 1,200-acre powered Matagorda County site plus the pending 505MW Long Ridge gas-plant deal doubles full-energization capacity to 4.8GW — another step in the pivot from pure mining to AI/HPC infrastructure. But the 2GW campus has no signed tenant; an entire leasing cycle separates the story from cash flow.

News — Citizens initiated at Outperform with a $24 target; Strategic Bitcoin Reserve policy chatter added sector fuel, with RIOT +5% and CLSK +6% alongside. Miner-to-AI-landlord conversion is this rally's shared script.

Short-term · 2–4 weeks
Neutral Sidelines

The intraday fade under the 20-day says speculation dominated the pop; bitcoin's price and tenant progress are two variables it controls neither of. The odds aren't legible.

Entry No participation until a volume-backed hold above $14 or a signed tenant landsStop —Target —
Long-term · months+
Neutral

Powered land is a real asset in the AI power famine, and the 4.8GW pipeline has option value; but the miner-to-landlord conversion needs leases, financing and execution — three proofs, none yet delivered.

  • A bitcoin downturn compresses cash flow and multiple at once
  • AI campus leasing falls short
  • Dilution funding the conversion capex
Community Voices
  • WSB · '4.8GW of power is the new oilfield' — the last crowd chanting this bought the top of the rig cycle; power stories still end with someone signing a leaseOriginal ↗
Institutional Views
  • 华尔街共识 · 15 analysts, average target $18.10 (+37% vs. spot), 1.47 rating
  • Citizens · Initiated Outperform, $24 target: the HPC pivot toward hyperscale customers drives the re-ratingSource ↗

Rapid Scan (7 names)

TickerCloseChangeScoreDirectionOne-line take
TD logoTDUS$119.75+1.00%7LongUp 1.0%, repairing the pullback and re-surfacing in both hot and breakout channels; Canadian bank momentum holds
NTAP logoNTAPUS$171.73+3.83%6NeutralUp 3.8%, a step from 52-week highs as AI-storage spillover lifts it; RSI 68 runs warm — wait for the dip
PEP logoPEPUS$137.86-3.26%5NeutralDown 3.3% on 1.9x volume toward 52-week lows; defensives are being systematically drained — another one after COST
ALNY logoALNYUS$312.79-3.31%6NeutralDown 3.3% on 5x volume after an intraday spike — gifted the same Ionis windfall yet closed red; ATTR money went to BridgeBio first
NU logoNUUS$13.67+2.24%6NeutralUp 2.2% in a +16.6% monthly LatAm fintech repair; the 200-day ($15.20) is the medium-term divide
PATH logoPATHUS$11.8+3.33%6NeutralUp 3.3%, secure above both averages as the AI-agent story transfuses the RPA veteran; the -28.5% YTD crater is still deep
FIG logoFIGUS$22.26+2.72%5NeutralUp 2.7% in a +14.2% weekly broken-IPO bounce with the 50-day reclaimed; $25 (the prior shelf) is the litmus test
Stock Brief 2026-07-10: Daily U.S. & HK Market Analysis Archive · Quant Brief